BJMO - volume 19, issue 1, january 2025
C. Fontaine MD, J. Collignon MD, P. Debruyne MD, PhD, L. Duck MD, E. Everaert MD, T. Feys MBA, MSc, C. Langenaeken MD, F. Lebrun MD, J. Mebis MD, E. Naert MD, P. Van Landuyt PharmD, S. Wuyts PharmD, C. van Marcke de Lummen MD, PhD, F. Vanryckeghem MD, V. Verschaeve MD, J. Klaskersky MD, PhD
Nausea and vomiting continue to be some of the more dreaded side effects of anticancer therapy. While advances in the prophylaxis of chemotherapy induced nausea vomiting (CINV), and guidance from international cancer societies have yielded important benefits for cancer patients, there remains an important need to further improve patient care. To address the need for a better CINV prophylaxis, and to respond to the introduction of new potentially emetogenic anticancer agents and the publication of new clinical trial data with anti-emetic agents, several international oncological societies have recently updated their guidelines for the prevention of CINV. The objective of this paper was to translate these new international recommendations to a Belgian context.
(BELG J MED ONCOL 2025;19(1):15–26)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
